Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<keyword id="6358777" type="LOCATION" weightage="20" keywordseo="New-Delhi">New Delhi</keyword>, <keyword id="472760" type="PERSON" weightage="20" keywordseo="Indian-pharma-companies">Indian pharma companies</keyword> are expected to benefit from improving demand in the US market, said <keyword id="1498859" type="COMPANY" weightage="20" keywordseo="India-Ratings-and-Research">India Ratings and Research</keyword> (Ind-Ra). As per the ratings agency, these companies have garnered 45% of all new Abbreviated New Drug Application (ANDA) approvals over the past nine months. Besides, Ind-Ra expects the regulatory environment to remain stringent. However, it said well-equipped companies would be able to take the advantage of a better pricing outlook emanating from supply shortages and recalls. "Indian companies have received a higher share of new ANDA approvals since April 2020 led by significant manufacturing facility clearances, GDUFA-II (Generic Drug User Fee Amendments), and a strong filing momentum aided by historical investments in R&amp;D," Ind-Ra added in a report. "Ind-Ra has seen an increasing drug demand since the start of the <keyword id="8902449" type="UNKNOWN" weightage="20" keywordseo="covid-19-pandemic">Covid-19 pandemic</keyword> led by supply chain issues, channel filling, and demand for Covid-19 led <keyword id="10461594" type="UNKNOWN" weightage="20" keywordseo="preventive-products">preventive products</keyword>. In the past, too, there was <keyword id="937715" type="PERSON" weightage="20" keywordseo="drug-shortage">drug shortage</keyword> in the US due to the exit of the large generic players from unviable products." "Overall drug shortages in the US are leading to moderate-to-stable pricing pressures." Furthermore, it cited that majority of the drug recalls (91%) from the US markets are from the non or least serious category (Class-II and III recall). Accordingly, only 'Class-I' drug recalls are serious in nature. SEE ALSO: <a href="https://www.businessinsider.in/business/news/ikea-india-cfo-says-she-still-has-3500-crore-to-be-spent-in-india-the-pandemic-has-changed-targets-but-not-the-investment-plan/articleshow/79790938.cms">INTERVIEW: Ikea CFO says she still has ₹3,500 crore to be spent in India⁠— the pandemic has changed targets but not the investment plan</a> <a href="https://www.businessinsider.in/science/health/news/india-will-produce-300-million-doses-of-the-russian-sputnik-v-covid-19-vaccine-next-year/articleshow/79795341.cms">India will produce 300 million doses of the Russian Sputnik V COVID-19 vaccine next year</a> <a href="https://www.businessinsider.in/stock-market/news/how-to-check-mrs-bectors-food-specialities-ipo-allotment-status-online/articleshow/79808672.cms">Mrs Bectors Food Specialities IPO allotment: Here’s how to check share allotment status</a>

Indian pharma companies to benefit from increasing demand in US, says report

<ul><li>Business Insider reached out to several experts to understand the impact of Trump’s new proposal to import <keyword id="971519" type="PERSON" weightage="20" keywordseo="cheaper-drugs">cheaper drugs</keyword> from other countries. </li><li>Some experts see this order providing good news for the Indian pharmaceutical companies; adding that it could help increase their global presence. </li><li>On the other hand, some experts believe that Trump’s plan to cut prescription drug prices could negatively impact <keyword id="1413836" type="PERSON" weightage="20" keywordseo="Indian-pharmaceutical-companies">Indian pharmaceutical companies</keyword> and may limit the opportunities ahead. </li></ul>US President Donald Trump, on July 25, proposed four orders that would allow the American government Singhto import cheaper drugs from abroad and provide it to American citizens at a lower price. While the move benefits American citizens, it also has a direct impact on the pharmaceutical industries of countries like Canada, China, and India. Previously, in 2018, Indian firms accounted for 35-40% of the global USFDA 971 approval, <a href="https://www.gbreports.com/article/the-worlds-pharmacy-indias-generic-drug-industry">according to Global Business Reports. </a> So what does this move mean for Indian pharmaceutical companies? Business Insider reached out to several experts to understand the impact of Trump’s new proposal to import cheaper drugs from other countries. Impact on Indian pharma companies According to Shailesh Shah, Senior Partner, and founder at Strta Consulting, the proposed order can be a piece of good news for the Indian pharmaceutical companies. “If the orders do pass, it will be a boom time for countries that are exporting lower cost patent expired copies to America. Irrespective of circumstances, their repurposed uses would increase. Their sales would go up.” Shah told Business Insider India. The proposed orders are also likely to increase the presence of Indian pharmaceutical industry globally, believes Dr. Shuchin Bajaj, Founder Director, <keyword id="9661943" type="COMPANY" weightage="20" keywordseo="ujala-cygnus-healthcare-services">Ujala Cygnus Healthcare Services</keyword>. Should Indian pharma companies be worried? On the other hand, some experts believe these orders might have a negative impact and may limit the opportunities for Indian pharmaceutical companies. “The impact of Donald Trump’s executive orders on Indian drug companies will be either neutral or negative. While the order related to the passing through of the rebates to patients will primarily impact the middlemen, the order which states that the US drug prices should be based on international pricing could negatively impact companies that sell speciality drugs and biosimilars,”Mahesh Singhi, Managing Director and Founder of Singhi Advisors told Business Insider India. Mr. Arvind Sharma, Partner, Shardul Amarchand Mangaldas &amp; Co believes these orders, if passed, might hamper the series of measures taken by the Indian government to strengthen the pharmaceutical sector. “It may be noted that the government has taken a series of measures to strengthen the pharma sector, including introducing the concept of pharma parks where investments will be made in common infrastructure and providing production incentives. Such measures have been introduced with a view to make the Indian pharma sector self-sufficient and encash on the global opportunity for this sector. The aforesaid orders make the situation complex and limit the opportunity for the pharma sector”. It is still too soon to determine the impact of the proposal “We need to wait for more specifics on the drugs covered etc but it's probably unlikely to impact the Indian pharma exporters much, since there has already been significant price erosion in the last three years,” Ms. Charu Sehgal, Partner and Leader, Life Sciences and Healthcare, <keyword id="6356108" type="COMPANY" weightage="20" keywordseo="deloitte-india">Deloitte India</keyword> Moreover, this news comes at a time when Donald Trump is facing re-election in the next few months, and this makes the execution of these orders a bit challenging. SEE ALSO: <a href="https://www.businessinsider.in/stock-market/news/mahindra-and-mahindra-finance-managing-director-gets-candid-about-the-rights-issue/articleshow/77212386.cms">EXCLUSIVE: M&amp;M Financial Managing Director gets candid about the rights issue, the bleak prospects for this year and why there should be no more loan moratorium</a> <a href="https://www.businessinsider.in/stock-market/news/india-stock-brokers-hit-by-sebi-direct-market-access/articleshow/77198064.cms">India's broking industry just got the shock of its life – SEBI may soon allow investors to trade directly on the exchanges</a> <a href="https://www.businessinsider.in/business/startups/news/these-10-indian-colleges-have-produced-indias-most-funded-startup-owners/slidelist/77140792.cms">These 10 Indian colleges have produced India’s most funded startup owners</a>

Boon or a bane: What does Trump’s latest proposal to import cheaper drugs mean for Indian pharma companies?

<ul><li>Katherine Eban’s “Bottle of Lies”, launched in US on May 14, warns Americans against generic drugs made abroad.</li><li>The book is an account of the lapses in good manufacturing practices by drug exporters to US.</li><li>Indian companies are big exporters of medicines to US and are already squeezed between shrinking prices and regulatory pressures.</li></ul> Drug makers in India have relied on Americans to buy a big chunk their produce for a long time now. It had paid off well for many years until recently. Between rising competition squeezing prices, regulatory pressure to keep prices lower, and an expanding lawsuit into a purported conspiracy, Indian companies have found the US market to be a tougher place than it ever was. The latest blow has come in the form of a new book, "Bottle of Lies", which "argues that generic drugs are poisoning us," <a href="https://www.nytimes.com/2019/05/13/books/review/bottle-of-lies-katherine-eban.html" data-type="tilCustomLink" target="_blank">according to the New York Times</a>. It's "an invaluable exposé, a reportorial tour de force and a well-turned epic," the reviewer David Dobbs added. The controversy that forms the heart of the book is nearly a decade old. Dinesh Thakur blew the lid on an Indian company Ranbaxy for cutting corners and compromising on quality of drugs before <a href="https://dineshthakur.com/about-2/" data-type="tilCustomLink" target="_blank">quitting the company in 2005</a>. The case unraveled over the years in courtrooms, Congressional hearings, and public discourse that damaged the reputation of India as the 'pharmacy of the world'. The <a href="https://in.reuters.com/article/ranbaxy-settlement-felony-usa-idINDEE94C0DA20130513" data-type="tilCustomLink" target="_blank">case has since been settled</a> at the US Federal Drug Administration (USFDA) for $500 million, <a href="https://www.livemint.com/Companies/tvbrlhX1YGdm7GshBC44VL/Sun-Pharma-completes-Ranbaxy-merger-shares-jump.html" data-type="tilCustomLink" target="_blank">Ranbaxy has been bought over</a> by Sun Pharma, India's largest drug maker with a <a href="https://www.sunpharma.com/sites/all/themes/sunpharma/images/annual/IR%20Presentation%20Feb%202018%20(INR).pdf" data-type="tilCustomLink" target="_blank">huge stake in the US market</a>. But the troubles of Indian drug makers are far from over. On one hand, there is a two-pronged pressure consistently squeezing drug prices-- one from <a href="https://www.businessinsider.in/The-Trump-administration-has-a-little-known-practice-in-the-pharma-industry-in-its-crosshairs/articleshow/64124087.cms" data-type="tilCustomLink" target="_blank">the Trump administration</a> and the other from the <a href="https://www.livemint.com/market/mark-to-market/us-disruption-may-have-singed-indian-pharma-but-it-is-emerging-stronger-1557253325315.html" data-type="tilCustomLink" target="_blank">rising competition</a> in generic drugs. Over the past three years, sales per marketed product (in US) have declined by about 30%, according to a report by global investment bank Nomura in March 2019. At the same time, <a href="https://www.businessinsider.in/seven-indian-pharma-companies-are-being-dragged-into-a-us-lawsuit-over-high-drug-prices/articleshow/69318841.cms" data-type="tilCustomLink" target="_blank">seven Indian companies</a> -- Sun Pharma, Dr Reddy’s Laboratories, Glenmark Pharma, Lupin, Wockhardt, Zydus Pharma and Aurobindo Pharma-- are facing a lawsuit in over 40 American states for acting like a cartel to keep drug prices up. "However, given intensifying competition due to faster generic approvals and regulatory headwinds, the litigation raises the risk associated with the US generics business for companies involved in the litigation," a report from an Indian brokerage, Motilal Oswal, on May 14 said. And Eban's book, which will only further worsen the narrative for the Indian companies, had the endorsement from none other than Dinesh Thakur. “The new book ‘Bottle of Lies’ exposes the truth – and it is critical that Congress hold hearings to address generic drug safety in America,” Thakur said at the book launch in Washington D.C. on Tuesday. Erin Fox, Senior Director of Drug Information and Support Services at University of Utah Health Care (UUHC), who was also present at the launch said that, "The current pass/fail system the U.S. has in place for generic manufacturers overseas is not working. We need either quality metrics for suppliers or more transparency to make quality-based purchasing decisions." Any regulatory action based on this advice will put Indian companies in a deeper pit than the one they are already in. SEE ALSO: <a href="https://www.businessinsider.in/one-chart-from-a-big-pharma-ceo-reveals-how-drug-pricing-in-the-us-really-works/articleshow/68174467.cms" data-type="tilCustomLink" target="_blank">One chart from a big pharma CEO reveals how drug pricing in the US really works</a> <a href="https://www.businessinsider.in/seven-indian-pharma-companies-are-being-dragged-into-a-us-lawsuit-over-high-drug-prices/articleshow/69318841.cms" data-type="tilCustomLink" target="_blank">Seven Indian pharma companies are being dragged into a US lawsuit over high drug prices</a>

A frightening new book on the safety of generic drugs could send India’s pharma industry into an even deeper pit

<ul><li>Over 40 states in the US have filed a lawsuit against 20 drugmakers led by Teva Pharmaceuticals, an Israeli firm, for allegedly conspiring to raise prices of drugs. </li><li>Seven Indian drugmakers - <keyword id="44642" type="CITY" weightage="20" keywordseo="Sun-Pharma">Sun Pharma</keyword>, Dr Reddy’s Laboratories, Glenmark Pharma, Lupin Wockhardt, Zydus Pharma and Aurobindo Pharma - have been named in the antitrust lawsuit. </li><li>The lawsuit alleges that the concerned pharmaceutical firms colluded to raise the prices of over 100 medicines.</li></ul> Over 40 states in the US have <a href="https://www.livemint.com/industry/manufacturing/top-indian-drug-makers-accused-of-fixing-prices-1557774708125.html">filed a lawsuit</a> against 20 drugmakers led by Teva Pharmaceuticals, an Israeli firm, for allegedly conspiring to raise prices of drugs in the US market. Seven Indian drugmakers - Sun Pharma, Dr Reddy’s Laboratories, Glenmark Pharma, Lupin Wockhardt, Zydus Pharma and Aurobindo Pharma - have been named in the antitrust lawsuit, which was filed at the end of last week following the culmination of a multi-year investigation into the US pharma industry. Sun Pharma’s share price on the Bombay Stock Exchange <a href="https://www.google.com/search?q=sun+pharma+share+price&amp;rlz=1C1GCEU_enIN820IN820&amp;oq=sun+pharma+share+price&amp;aqs=chrome..69i57j0l5.4788j1j4&amp;sourceid=chrome&amp;ie=UTF-8">fell 13% </a>yesterday before recovering. The lawsuit alleges that the concerned pharmaceutical firms colluded to raise the prices of over 100 medicines and divide up the addressable market for the medicines as opposed to competing normally against each other. Teva is said to be <a href="https://www.philly.com/business/generics-teva-pennsylvania-new-jersey-drugs-price-fixing-20190513.html">the driving force </a>behind the collusion. Between 2013 and 2015, the Israel drugmaker reportedly fixed prices on 86 medicines, the complaint from the states alleged. The price increases on some drugs were as high as 1,000%. The drugmakers have to deal with more than just the lawsuit from the states. Even the US Department of Justice is investigating the companies for antitrust violations. Speaking on the matter, a spokesperson for Sun Pharma told <a href="https://www.livemint.com/industry/manufacturing/top-indian-drug-makers-accused-of-fixing-prices-1557774708125.html">Mint</a>, ““We believe the allegations made in these lawsuits are without merit and we will continue to vigorously defend against them." If successfully argued, the lawsuit could result in billions of dollars worth of fines for the concerned companies. The fines for Indian pharma firms are expected to be in <a href="https://timesofindia.indiatimes.com/business/india-business/7-indian-pharma-cos-face-lawsuits-from-over-40-us-states/articleshow/69315711.cms">the tens of millions of range</a>, since their participation was reportedly limited. For their part, the drugmakers have argued that the price increases were a result of market factors like supply shocks and consolidation among rivals. SEE ALSO: <a href="https://www.businessinsider.in/generic-drugs-are-americas-solution-to-high-branded-drug-prices-but-recent-events-suggest-the-markets-not-working/articleshow/67200320.cms">Generic drugs are America's solution to high branded drug prices. But recent events suggest the market's not working</a>

Seven Indian pharma companies are being dragged into a US lawsuit over high drug prices

<ul><li>Pharma company stocks is the only sector gaining in the weak market on Wednesday on optimism to sell anti-covid drugs approved by the drug regulator.</li><li>The pharma regulator gave approval to sell <keyword id="10880838" type="General" weightage="20" keywordseo="molnupiravir" source="Orion">Molnupiravir</keyword> drug, which is an anti-COVID pill, for emergency use in the country.</li><li><keyword id="44642" type="General" weightage="20" keywordseo="sun-pharma" source="Orion">Sun Pharma</keyword>, <keyword id="6357157" type="General" weightage="20" keywordseo="cipla" source="Orion">Cipla</keyword>, Torrent Pharma and <keyword id="4569824" type="General" weightage="20" keywordseo="strides-pharma" source="Orion">Strides Pharma</keyword> have already announced plans to launch their version of this pill soon amid rising spread of Omicron in the country.</li></ul>Pharmaceutical company stocks were the top gainers in a weak market on December 29 as the segment cheered pharma regulator’s — Drugs Controller General of India (DCGI) — approval of anti-covid pill for emergency use in the country. The move comes amid rising spread of Omicron cases in the country. Indian companies will manufacture a generic version of Merck's anti-COVID pill Molnupiravir in India. Molnupiravir is an antiviral medication that is used to treat COVID-19 in those infected. The drug was developed by US-based firms Merck and Ridgeback Biotherapeutics. The development has brought some optimism for pharma stocks that have been underperforming the market for more than a year. <table style="border-width: initial; border-style: none;"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Top performing pharma stocks on December 29 </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">% of change </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">% returns in 2021 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Laurus Labs </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">2.38% </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">53% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Dr Reddy’s Laboratories </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">1.61% </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">-8% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Sun Pharmaceuticals </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">1.58% </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">38% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Lupin </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">1.41% </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">-7% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Alembic Pharmaceuticals </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">1.13% </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">-22% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Divi’s Laboratories </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">1.67% </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">19% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cipla </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">1.08% </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">14% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Glenmark Pharmaceuticals </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">1.07% </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">3% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Natco Pharma </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">1% </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">-7% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Biocon </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">0.97% </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">-22% </td></tr></tbody></table> While Indian companies are manufacturing a generic version from US-based pill, they will market the pill under their respective brands and sell them in pharmacies and COVID-19 treatment centres. <table style="border-width: initial; border-style: none; table-layout: fixed; width: 468pt;"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Companies </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Anti-COVID pill </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Sun Pharmaceuticals </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Molxvir </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Torrent Pharmaceuticals </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Molnutor </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cipla </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cipmolnu </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Strides Pharma Science </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Stripiravir </td></tr></tbody></table>Earlier this year, US-based pharma company Merck had signed non-exclusive voluntary licensing agreements with over eight Indian companies to manufacture and supply generic versions of Molnupiravir in over 100 low and middle-income countries (LMICs), including India. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/the-ipo-excitement-may-be-softer-in-2022-but-that-can-be-a-good-thing-for-investors/articleshow/88557624.cms">The IPO excitement may be softer in 2022 but that can be a good thing for investors</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/startups/news/india-is-home-to-81-unicorns-now-as-mamaearth-globalbees-make-it-to-the-list/articleshow/88558418.cms">India is home to 81 unicorns now as Mamaearth, Globalbees make it to the list</a>

Sun Pharma, Dr Reddy’s Lab, Divi’s Lab and other pharma stocks rally on regulator’s nod to make anti-COVID pill

<ul><li>The American drug regulator approved 953 new generic drugs between October 2018 and June 2019.</li><li>This is the highest number of approvals in the first nine months of any fiscal year from the USFDA, according to a report.</li><li>While the new approvals will put pressure on existing drugs to be cheaper, the silver lining for companies is that new applications have slowed down.</li></ul>The United States Food and Drug Administration (USFDA) has generously doled out approvals for new drugs and that is likely to show in the profits of Indian drug makers like <keyword id="44642" type="CITY" weightage="20" keywordseo="Sun-Pharma">Sun Pharma</keyword>, <keyword id="46698" type="CITY" weightage="20" keywordseo="Lupin">Lupin</keyword>, <keyword id="7875008" type="UNKNOWN" weightage="20" keywordseo="dr-redddys-laboratories">Dr Redddy's Laboratories</keyword>, and <keyword id="70473" type="COMPANY" weightage="20" keywordseo="Aurobindo-Pharma">Aurobindo Pharma</keyword> when the earnings start tumbling out this month. The American drug regulator approved 953 new generic drugs between October 2018 and June 2019. This is the highest number of approvals in the first nine months of any fiscal year from the USFDA, according to a report from Ashika Institutional Research. Companies have been battling the pricing pressure in US for a while now and the profit squeeze has taken a lot out of stock prices in recent years. On one hand, there is a two-pronged pressure consistently squeezing drug prices-- one from <a href="https://www.businessinsider.in/The-Trump-administration-has-a-little-known-practice-in-the-pharma-industry-in-its-crosshairs/articleshow/64124087.cms" data-type="tilCustomLink" target="_blank">the Donald Trump administration</a> and the other from the <a href="https://www.livemint.com/market/mark-to-market/us-disruption-may-have-singed-indian-pharma-but-it-is-emerging-stronger-1557253325315.html" data-type="tilCustomLink" target="_blank">rising competition</a> in generic drugs. Over the past three years, sales per marketed product (in US) have declined by about 30%, according to a report by global investment bank Nomura in March 2019. At the same time, <a href="https://www.businessinsider.in/seven-indian-pharma-companies-are-being-dragged-into-a-us-lawsuit-over-high-drug-prices/articleshow/69318841.cms" data-type="tilCustomLink" target="_blank">seven Indian companies</a> -- Sun Pharma, Dr Reddy’s Laboratories, Glenmark Pharma, Lupin, Wockhardt, Zydus Pharma and Aurobindo Pharma-- are facing a lawsuit in over 40 American states for acting like a cartel to keep drug prices up. "However, given intensifying competition due to faster generic approvals and regulatory headwinds, the litigation raises the risk associated with the US generics business for companies involved in the litigation," a report from an Indian brokerage, Motilal Oswal, on May 14 said. At rock bottom While the new approvals will put pressure on existing drugs to be cheaper, the silver lining for companies is that new applications have slowed down. "We are seeing mild slowdown with total 696 ANDAs submitted in the first 9 months of the fiscal year, down 8% (YoY). As major generic companies continue to exit unattractive products, ANDA (generic drug) submissions are seeing this slowdown," the report said. In terms of profit margins, Indian drug makers, who rely a lot on the US market for their revenue, have little to lose and a lot to gain from the low base of previous years. According to estimates from Karvy, the margin for most companies is expected to have widened significantly in the three months ended June 2019, compared to the same period a year earlier. <table style="width: 166pt;"> </colgroup> <tbody><tr> <td class="xl66" style="height:15.0pt;width:82pt">Company</td> <td class="xl67" style="border-left-width: initial; border-left-style: none; width: 84pt;">Profit Margin</td> </tr> <tr> <td class="xl68" style="height: 15pt; border-top-width: initial; border-top-style: none;">Lupin</td> <td class="xl69" style="border-top-width: initial; border-top-style: none; border-left-width: initial; border-left-style: none;">+732 basis points</td> </tr> <tr> <td class="xl68" style="height: 15pt; border-top-width: initial; border-top-style: none;">Sun Pharma</td> <td class="xl69" style="border-top-width: initial; border-top-style: none; border-left-width: initial; border-left-style: none;">-253 basis points</td> </tr> <tr> <td class="xl68" style="height: 15pt; border-top-width: initial; border-top-style: none;">Torrent Pharma</td> <td class="xl69" style="border-top-width: initial; border-top-style: none; border-left-width: initial; border-left-style: none;">+118 basis points</td> </tr> <tr> <td class="xl68" style="height: 15pt; border-top-width: initial; border-top-style: none;">Cadila Health</td> <td class="xl69" style="border-top-width: initial; border-top-style: none; border-left-width: initial; border-left-style: none;">-45 basis points</td> </tr> <tr> <td class="xl68" style="height: 15pt; border-top-width: initial; border-top-style: none;">Dr Reddy's Labs</td> <td class="xl69" style="border-top-width: initial; border-top-style: none; border-left-width: initial; border-left-style: none;">+217 basis points</td> </tr> <tr> <td colspan="2" class="xl70" style="border-right:1.0pt solid black; height:15.0pt;width:166pt">Source: Karvy Stock Broking </td> </tr> <tr> <td colspan="2" class="xl72" style="border-right:1.0pt solid black; height:15.75pt">100 basis points make 1%</td> </tr></tbody></table> SEE ALSO: <a href="https://www.businessinsider.in/donald-trump-on-generic-drugs-indian-pharma-and-katherine-ebans-new-book-with-dinesh-thakur/articleshow/69407566.cms" data-type="tilCustomLink" target="_blank">The man who brought Ranbaxy to its knees is pushing for ‘Made in India’ tag on drugs sold in US</a>

USFDA has set a new record in generic drug approvals this year-- but Indian drug makers have a lot to gain and little to lose

<ul><li>Actor <keyword id="6354625" type="General" weightage="80" keywordseo="vijay-sethupathi" source="Orion">Vijay Sethupathi</keyword> has been roped in as the brand ambassador of Mankid Pharma.</li><li>As a part of the association, <keyword id="146847" type="General" weightage="80" keywordseo="mankind-pharma" source="Orion">Mankind Pharma</keyword> will donate Rs 31 lakh to the Film Employees Federation of South India (FEFSI).</li></ul>Pharmaceutical company <keyword id="111790" type="General" weightage="100" keywordseo="mankind" source="Orion">Mankind</keyword> Pharma has announced its association with Vijay Sethupathi, an Indian actor and producer who predominantly has contributed in the Tamil cinema. In lieu of this association, Mankind Pharma, the company will be donating an amount of Rs 31 lakh to the Film Employees Federation of South India (FEFSI). FEFSI is an Indian organisation consisting of technicians from the <keyword id="6412552" type="General" weightage="20" keywordseo="tamil-film-industry" source="Orion">Tamil Film Industry</keyword> in Tamil Nadu, India. The amount donated will help all those who are facing a slowdown due to the pandemic and will support the growth of the organization and its members. Vijay Sethupathi has won 15 awards in the category of Best Actor which includes Filmfare Award- Tamil, <keyword id="128899" type="General" weightage="20" keywordseo="national-film-award" source="Orion">National Film Award</keyword>, <keyword id="12247905" type="General" weightage="20" keywordseo="vijay-award" source="Orion">Vijay Award</keyword> for Best actor and many more. Speaking on the partnership, Sethupathi said, “It is a pleasure to partner with Mankind Pharma as the brand ambassador and represent the brand in the southern market. The company perfectly justifies the true meaning of ‘Mankind’ and the motto of ‘Serving Life’ in the industry. I am honoured to be a part of the Mankind Pharma family and hope to serve the society together.” Speaking on the occasion, <keyword id="4921166" type="General" weightage="20" keywordseo="Rajeev-Juneja" source="Orion">Rajeev Juneja</keyword>, Managing Director and Vice Chairman, Mankind Pharma said, “We believe that Vijay Sethupathi is an ideal personality for us as a brand ambassador and has an emotional connect with the audience which is why people call him “People’s Treasure”. Both Mankind Pharma and the superstar have a common synergy and thought process of serving life in the country, and we feel this mutual alliance will be a prolific one for both of us. We at Mankind Pharma always selflessly contribute towards the betterment of the society and believe in serving life, we hope that the token amount donated to FEFSI will help provide assurance towards the growth of the company. Together we will continue to selflessly contribute towards the betterment of the society.” Mankind Pharma aspires to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs.

Mankind Pharma ropes in Vijay Sethupathi as its brand ambassador

New York, Apr 7 () A New Jersey-based generic pharmaceutical company, co-founded by two Indian-Americans has donated millions of hydroxychloroquine sulfate tablets to Louisiana, New York and Texas to help COVID19 patients.Amneal Pharmaceuticals has pledged to donate 400,000 hydroxychloroquine sulfate tablets to the State of Louisiana to help respond to the COVID-19 health emergency, according to a press release dated March 30 from Louisiana Attorney General Jeff Landry.However, the US government's top infectious disease specialist Anthony Fauci has been vocal about his concern that there is not enough evidence to suggest that Hydroxychloroquine is the drug that cures COVID19.The release said that the large donation will go toward clinical trials and patient treatment in Louisiana.Hydroxychloroquine, an old and inexpensive drug used to treat malaria, is seen as a viable therapeutic solution by President Trump to coronavirus that has so far killed more than 10,000 Americans and infected over 3.6 lakh within weeks. Bridgewater, New Jersey-headquartered Amneal was founded in 2002 by Chirag Patel and Chintu Patel, who are also the Co-CEOs. "Amneal has donated millions of hydroxychloroquine sulfate tablets in total to states other than Louisiana, including New York and Texas, and stated they will provide more as needed. The company also announced donations of products directly to hospitals across the country," the release added.The press release from the Louisiana Attorney General quoted Chirag and Chintu Patel as saying that "all of us at Amneal are committed to supporting our communities in the global fight against COVID-19. We are working with urgency to assist the hardest hit states and hospitals around the country to benefit as many patients as possible during this critical time."Amneal's hydroxychloroquine sulfate tablets are approved by the United States Food and Drug Administration (FDA) to treat malaria, rheumatoid arthritis, lupus, childhood arthritis, and other autoimmune diseases. Hydroxychloroquine is not FDA-approved for the treatment of COVID-19; but it has been identified as a possible treatment for COVID-19, and the US Government has requested its immediate availability, the release said.Landry thanked Amneal for the donation and said "it is important we all work together to help solve the COVID-19 crisis." The Louisiana State University School of Medicine is working to launch two different clinical trials using hydroxychloroquine in relation to COVID-19. One trial will utilise hydroxychloroquine on those who have significant COVID-19 disease.The other trial protocol will use and test the drug as a preventative measure for those healthcare workers on the front lines battling the epidemic. Trials will be conducted at the University Medical Center in New Orleans and at the LSU Medical School locations in Baton Rouge and Lafayette.Dean of LSUHSC School of Medicine Steve Nelson said the donation will allow them to conduct clinical trials examining how hydroxychloroquine may help clear the virus from the lungs of infected patients and to potentially help shield healthcare workers who are on the front lines treating patients."The hydroxychloroquine donation by Amneal comes at an important time. The Louisiana Board of Pharmacy has noted serious concerns over the availability of this drug and has issued specific guidance on the dispensing of the drug, including its March 25th guidance noting that it should be dispensed for COVID-19 when the prescription bears a COVID-19 diagnosis," the release said. YAS PMSPMS

Pharma company founded by Indian-Americans donates hydroxychloroquine tablets in US

New Delhi, Dec 5 () Drug firm Mankind Pharma on Thursday said it has launched its generic Dydrogesterone tablets for treatment of infertility and pregnancy related complications in the Indian market.
 With the launch, the company has become the first Indian and second global firm to develop the drug, Mankind Pharma said in a statement.
 The company's product is generic version of Abbott's Duphaston tablets, it added.
 The manufacturing process of Dydrogesterone is very complex as it involves conversion of natural progesterone, the statement said.
 Progesterone is a natural hormone involved in menstrual cycle, implantation and in successful maintenance of pregnancy. 
 Any deficiency of progesterone during different stages of reproductive process can cause infertility, menstrual disorders and miscarriage, it added.
 "The launch of this drug is an important milestone for Mankind Pharma. We are the first Indian pharmaceutical company to develop this drug and second company in the world," Mankind Group founder and Chairman R C Juneja said.
 Currently the drug is being launched only in India, post that the company is planning to launch the drug in countries where it already has a presence, he added.
 Mankind has a strong presence in pharmaceutical, veterinary, OTC &amp; FMCG segments. 
 The company is present across North America, Asia, Africa and CIS countries. AKT RVK

Manking Pharma launches drug for treatment of infertility in India

<ul><li>The shares of <keyword id="6444828" type="ORGANIZATION" weightage="20" keywordseo="gland-pharma">Gland Pharma</keyword> listed at a premium of 12% over the issue price band.</li><li>In minutes after its debut, the shares gained over 6% and were trading at ₹1795.30 a piece at 10:04 am.</li><li>Gland Pharma's total market cap rose to ₹28,636.54 crore. </li></ul>The ₹6,480 crore initial public offering of the Chinese promoter Fosun Pharma-backed Gland Pharma made a lot of money for its IPO investors despite a subdued response during the public issue. Top brokerages had advised caution on Gland Pharma, given its China connection. However, investors could not resist its strong financial performance and the fear of missing out has helped the company record a stellar debut on Dalal Street. The shares listed at a premium of 12% over the issue price band. And, in minutes after listing debut the shares gained over 6% and were trading at ₹1795.30 a piece at 10:04 am in a firm market. This is the 13th company to list this year and the largest ever public issue in the Indian pharma industry. Gland Pharma total market cap rose to ₹28,636.54 crore at 10:03 am. A total traded quantity of 1.39 lakh shares changed hands on BSE amounting to a turnover of ₹23.86 crore. The company will trade with the symbol of ‘GLAND’ on the Indian stock exchanges. <div type="image" title="Gland Pharma share" msid="79316011" hostid="261"></div> Rising demand for Gland Pharma So far this year, nearly every company that recorded a tepid response during their IPO saw a discounted listing. And, the IPO’s of UTI AMC, Likhitha Infrastructure and Angel Broking are proof of that. However, the shares of Gland Pharma were piping hot in the grey market ahead of its listing, and the market premium suggested an upside of <a href="https://www.businessinsider.in/stock-market/news/gland-pharma-shares-demand-is-rising-in-the-grey-market-ahead-of-its-listing-tomorrow/articleshow/79302810.cms">7% a day before listing</a>. Given that the Chinese promoter backs it, <a href="https://www.businessinsider.in/stock-market/news/heres-all-you-need-to-know-about-indias-largest-pharmaceutical-ipo-gland-pharma/articleshow/79125211.cms">top brokerages had advised caution</a>, despite its strong financial background, growing industry and diversified portfolio. Choice research report for its IPO highlighted that anti-Chinese sentiment after the recent geopolitical tension in the Galwan valley may disrupt its business. What worked for Gland Pharma? Strong balance sheet Gland Pharma has a successful track record of operating a B2B model with leading pharmaceutical companies such as Sagent Pharmaceuticals and Apotex as well as Fresenius Kabi USA and Athenex Pharmaceutical Division in the United States and the Rest of the world. <table style="border-width: initial; border-style: none;"></colgroup><tbody><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Manufacturing facilities </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">2 sterile injectables facilities </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">1 Penems facility </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">1 oncology facility </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">3 API facilities </td></tr></tbody></table> <div type="image" title="Gland Pharma profit and revenue (2)" msid="79317475" hostid="261"></div> Diversified business — spread over 60 countries With its business spread over 60 countries, the company has a great track record of revenue delivery and profitability across the United States, Europe, Canada, Australia, India and the rest of the world, according to Axis Securities. <div type="image" title="Gland Pharma Revenue break up" msid="79317490" hostid="261"></div> As of June 30, the company earns nearly 63% of its revenue from the US and nearly 15% from India — these two countries are the biggest market for Gland Pharma.The expansion in various other countries helps in offsetting the slowdown impact in a particular region or a country. SEE ALSO: <a href="https://www.businessinsider.in/tech/apps/news/pubg-mobile-india-was-supposed-to-launch-today/articleshow/79315462.cms" data-type="tilCustomLink">PUBG Mobile India was rumoured to launch today — but there is no official update from the company</a> <a href="https://www.businessinsider.in/stock-market/news/vodafone-idea-shares-jump-after-selling-stake-in-indus-towers-for-3760-crore/articleshow/79316662.cms" data-type="tilCustomLink">Vodafone Idea soars nearly 5% on fund infusion from Indus Towers stake sale</a>

You Searched For "Indian pharma companies" and got 10 results

Indian pharma companies to benefit from increasing demand in US, says report

IANS

Boon or a bane: What does Trump’s latest proposal to import cheaper drugs mean for Indian pharma companies?

BI India Bureau

A frightening new book on the safety of generic drugs could send India’s pharma industry into an even deeper pit

Sriram Iyer

Seven Indian pharma companies are being dragged into a US lawsuit over high drug prices

BI India Bureau

Sun Pharma, Dr Reddy’s Lab, Divi’s Lab and other pharma stocks rally on regulator’s nod to make anti-COVID pill

Bhakti Makwana

USFDA has set a new record in generic drug approvals this year-- but Indian drug makers have a lot to gain and little to lose

Sriram Iyer

Mankind Pharma ropes in Vijay Sethupathi as its brand ambassador

BI India Partner

Pharma company founded by Indian-Americans donates hydroxychloroquine tablets in US

PTI

Manking Pharma launches drug for treatment of infertility in India

PTI

FOMO helps Gland Pharma swell on debut

Navdeep Yadav

Popular Keywords

Buying Guides